A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

Recruiting

Phase 3

MirikizumabA Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

Sponsor:

Eli Lilly and Company

Code:

NCT04844606

Conditions

Ulcerative Colitis

Ulcerative Colitis Chronic

Inflammatory Bowel Diseases

Crohn's Disease

Eligibility Criteria

Sex: All

Age: 2 - 19

Healthy Volunteers: Not accepted

Interventions

Mirikizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-30. This information was provided to ClinicalTrials.gov by Eli Lilly and Company on 2025-09-23.